[HTML][HTML] A phase III study of belatacept‐based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)

F Vincenti, B Charpentier, Y Vanrenterghem… - American Journal of …, 2010 - Elsevier
Belatacept, a costimulation blocker, may preserve renal function and improve long‐term
outcomes versus calcineurin inhibitors in kidney transplantation. This Phase III study
(Belatacept Evaluation of Nephroprotection and Efficacy as First‐line Immunosuppression
Trial) assessed a more intensive (MI) or less intensive (LI) regimen of belatacept versus
cyclosporine in adults receiving a kidney transplant from living or standard criteria deceased
donors. The coprimary endpoints at 12 months were patient/graft survival, a composite renal …